These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Lorenzl S; Buerger K; Hampel H; Beal MF Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia. Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498 [TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283 [TBL] [Abstract][Full Text] [Related]
5. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Lorenzl S; Albers DS; Narr S; Chirichigno J; Beal MF Exp Neurol; 2002 Nov; 178(1):13-20. PubMed ID: 12460604 [TBL] [Abstract][Full Text] [Related]
7. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454 [TBL] [Abstract][Full Text] [Related]
8. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. Lorenzl S; Albers DS; Chirichigno JW; Augood SJ; Beal MF J Neurol Sci; 2004 Mar; 218(1-2):39-45. PubMed ID: 14759631 [TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151 [TBL] [Abstract][Full Text] [Related]
10. Matrix Remodeling Enzymes as Potential Fluid Biomarkers of Neurodegeneration in Alzheimer's Disease. Bašić J; Milošević V; Djordjević B; Stojiljković V; Živanović M; Stefanović N; Aracki Trenkić A; Stojanov D; Jevtović Stoimenov T; Stojanović I Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891891 [TBL] [Abstract][Full Text] [Related]
11. Elevated plasma angiogenesis factors in Alzheimer's disease. Qin W; Jia X; Wang F; Zuo X; Wu L; Zhou A; Li D; Min B; Wei C; Tang Y; Xing Y; Dong X; Wang Q; Gao Y; Li Y; Jia J J Alzheimers Dis; 2015; 45(1):245-52. PubMed ID: 25690662 [TBL] [Abstract][Full Text] [Related]
12. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis. Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Ulrich D; Hrynyschyn K; Pallua N Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511 [TBL] [Abstract][Full Text] [Related]
14. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659 [TBL] [Abstract][Full Text] [Related]
15. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936 [TBL] [Abstract][Full Text] [Related]
16. Circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with incisional hernia. Henriksen NA; Sørensen LT; Jorgensen LN; Agren MS Wound Repair Regen; 2013; 21(5):661-6. PubMed ID: 23927724 [TBL] [Abstract][Full Text] [Related]
17. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Brunner S; Kim JO; Methe H Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234 [TBL] [Abstract][Full Text] [Related]
18. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis. Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412 [TBL] [Abstract][Full Text] [Related]
19. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675 [TBL] [Abstract][Full Text] [Related]